{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:58:58Z","timestamp":1792033138723,"version":"4.4.0"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T00:00:00Z","timestamp":1476144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Eli Lilly Japan K.K. ProScribe's services"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis, a chronic, immune\u2010mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open\u2010label study was to evaluate the long\u2010term efficacy and safety of ixekizumab, a humanized, anti\u2010interleukin\u201017A monoclonal antibody, in Japanese patients with plaque psoriasis (<jats:italic>n<\/jats:italic> = 78, including 11 psoriatic arthritis), erythrodermic psoriasis (<jats:italic>n<\/jats:italic> = 8) and generalized pustular psoriasis (<jats:italic>n<\/jats:italic> = 5). Ixekizumab was administrated s.c. at baseline (week 0, 160 mg), from weeks 2 to 12 (80 mg every 2 weeks), and from weeks 16 to 52 (80 mg every 4 weeks). At week 52, 92.3% of patients with plaque psoriasis achieved Psoriasis Area and Severity Index (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>) 75, 80.8% achieved <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> 90, 48.7% achieved <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> 100, and 52.6% had remission of plaques (by static Physician Global Assessment, <jats:styled-content style=\"fixed-case\">sPGA<\/jats:styled-content> [0]). Difficult to treat areas of psoriasis (nail or scalp) also responded to ixekizumab. All patients with psoriatic arthritis who were assessed (5\/5) achieved an American College of Rheumatology 20 response. Most patients with erythrodermic psoriasis or generalized pustular psoriasis responded to ixekizumab and the clinical outcome was maintained over 52 weeks (75% and 60% of patients achieved <jats:styled-content style=\"fixed-case\">sPGA<\/jats:styled-content> [0, 1] at week 52, respectively). Mostly mild or moderate treatment\u2010emergent adverse events were reported by 79 of 91 patients; the most common were nasopharyngitis, eczema, seborrheic dermatitis, urticaria and injection site reactions. In conclusion, 52\u2010week ixekizumab treatment was efficacious and well tolerated in Japanese patients with plaque psoriasis. Efficacy was also observed in patients with erythrodermic psoriasis, generalized pustular psoriasis and psoriatic arthritis.<\/jats:p>","DOI":"10.1111\/1346-8138.13622","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T15:30:39Z","timestamp":1476372639000},"page":"355-362","source":"Crossref","is-referenced-by-count":183,"title":["Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52\u2010week, open\u2010label, phase 3 study (<scp>UNCOVER<\/scp>\u2010J)"],"prefix":"10.1111","volume":"44","author":[{"given":"Hidehisa","family":"Saeki","sequence":"first","affiliation":[{"name":"Department of Dermatology Nippon Medical School Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Nakajo","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeko","family":"Ishii","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Morisaki","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Aoki","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Cameron","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olawale O.","family":"Osuntokun","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Japanese Ixekizumab Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,10,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S67534"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.048"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12773"},{"key":"e_1_2_7_8_1","first-page":"815","article-title":"Practice guidelines for generalized pustular psoriasis (GPP): treatment guidelines incorporating TNF\u2010a inhibitor","volume":"120","author":"Iwatsuki K","year":"2010","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1246"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_7_13_1","first-page":"2576","article-title":"Activity indices in rheumatoid arthritis","volume":"27","author":"Villaverde V","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12996"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.039"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141598"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315582354"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202646"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13622","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.13622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:37:28Z","timestamp":1695472648000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.13622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,11]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/1346-8138.13622"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.13622","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,11]]}}}